Jump to content

Xiaole Shirley Liu

Edit links
From Wikipedia, the free encyclopedia
Xiaole Shirley Liu
Born
刘小乐
Alma materPeking University
Smith College (BA)
Stanford University (PhD)
AwardsISCB Fellow (2019)[1]
Breast Cancer Research Foundation Investigator
ISCB Innovator Award (2020)
Benjamin Franklin Award (Bioinformatics) (2020)
AIMBE Fellow (2022)
Scientific career
Fields
InstitutionsDana–Farber Cancer Institute
Harvard University
GV20 Therapeutics
ThesisDiscovery of transcription factor binding sites using computational statistics (2002)
Doctoral advisorDouglas Brutlag[3]
Jun S. Liu[4]
Websiteliulab-dfci.github.io

Xiaole Shirley Liu (刘小乐) is computational biologist, cancer researcher, and entrepreneur.[4][2][5][6][7] She has been a Professor in the Department of Data Sciences at the Dana-Farber Cancer Institute and Harvard T.H. Chan School of Public Health. She is now the co-founder and CEO of GV20 Therapeutics.

Early life

[edit]

Xiaole Shirley Liu was born 刘小乐 in Tianjin China to Meilun Liu and Xingke Hu, both on the faculty of Tianjin University.

Education

[edit]

Xiaole Liu attended Peking University in 1992–1994. She transferred to Smith College and graduated Summa cum laude in 1997 double majoring in biochemistry and computer science. Her research thesis, supervised under Steve Williams, was awarded the Highest Departmental Honors in Biochemistry.

She then went to Stanford University and got her Ph.D. in Biomedical Informatics and Ph.D. minor in Computer Science in 2002. Her thesis committee included Douglas Brutlag, Jun S. Liu, Russ Altman, Patrick O. Brown and Rob Tibshirani.[3] She added Shirley as her middle name after Ph.D., and used X. Shirley Liu in her publications.

Career

[edit]

Shirley Liu research work focused on algorithm development and data integration modeling for translational cancer research. Her group developed widely used algorithms for modeling transcriptional and epigenetic gene regulation (MACS, Cistrome, MDscan, BETA), analyzing CRISPR screens (MAGeCK), and characterizing tumor immunity (TIMER, TIDE, TRUST). She also contributed to the discovery of cancer drug response biomarkers, drug resistance mechanisms, and effective combination therapies.

Awards and honours

[edit]

X. Shirley Liu was elected a Fellow of the International Society for Computational Biology (ISCB) in 2019 for her “outstanding contributions to the fields of computational biology and bioinformatics”.[1]

References

[edit]
  1. ^ a b Anon (2019). "ISCB Fellows". iscb.org. International Society for Computational Biology. Archived from the original on 2019-03-30.
  2. ^ a b Xiaole Shirley Liu publications indexed by Google Scholar Edit this at Wikidata
  3. ^ a b Liu, Xiaole Shirley (2002). Discovery of transcription factor binding sites using computational statistics (PhD thesis). Stanford University. OCLC 84915802. ProQuest 305549892. Closed access icon
  4. ^ a b Xiaole Shirley Liu at the Mathematics Genealogy Project Edit this at Wikidata
  5. ^ Xiaole Shirley Liu's ORCID 0000-0003-4736-7339
  6. ^ Xiaole Shirley Liu at DBLP Bibliography Server Edit this at Wikidata
  7. ^ Zhang, Yong; Liu, Tao; Meyer, Clifford A; Eeckhoute, Jérôme; Johnson, David S; Bernstein, Bradley E; Nussbaum, Chad; Myers, Richard M; Brown, Myles; Li, Wei; Liu, X Shirley (2008). "Model-based Analysis of ChIP-Seq (MACS)". Genome Biology. 9 (9): R137. doi:10.1186/gb-2008-9-9-r137. ISSN 1465-6906. PMC 2592715. PMID 18798982.


Stub icon

This article about a biologist is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Xiaole_Shirley_Liu&oldid=1211949829"